For example, death from colon inflammation is more frequent in patients receiving anti-CTLA-4 drugs [46,47,48], while death from lung inflammation occurs more in patients receiving anti-PD-1 or anti-PD-L1 drugs [43,49,50]. Here, CTLA4 is linked to colitis.